Showing results (401-410 of 423) with videos related to
Sort By:
Pageof 43
Haematologica|November 9, 2014
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.American Journal of Physiology. Renal Physiology|May 26, 2005
Zebrafish slc4a2/ae2 anion exchanger: cDNA cloning, mapping, functional characterization, and localizationBoris E Shmukler, Christine E Kurschat, Gabriele E Ackermann, et al.Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|February 5, 2026
International Society for Diseases of the Esophagus consensus on the diagnosis and treatment of anastomotic leak after esophagectomySanne K Stuart, Jobbe M G Lemmens, Grard A P Nieuwenhuijzen, et al.Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.Current Treatment Options in Oncology|January 15, 2003
Oral cancer treatmentTerry A Day, Betsy K Davis, M Boyd Gillespie, et al.Nature Genetics|February 6, 2007
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genomeNathaniel D Heintzman, Rhona K Stuart, Gary Hon, et al.Molecular Psychiatry|April 15, 2022
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophreniaSamantha V Abram, Brian J Roach, Susanna L Fryer, et al.The ISME Journal|August 12, 2017
Feathermoss and epiphytic Nostoc cooperate differently: expanding the spectrum of plant-cyanobacteria symbiosisDenis Warshan, Josh L Espinoza, Rhona K Stuart, et al.British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.Pageof 43